Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Moodys
Boehringer Ingelheim
Fish and Richardson
Covington

Generated: August 21, 2019

DrugPatentWatch Database Preview

Patent: 8,071,645

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,071,645
Title:Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
Abstract: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.
Inventor(s): Newell; M. Karen (Colorado Springs, CO), Newell; Evan (Toronto, CA), Villalobos-Menuey; Elizabeth (Colorado Springs, CO)
Assignee: The Regents of the University of Colorado (Denver, CO)
Application Number:10/866,141
Patent Claims:see list of patent claims

Details for Patent 8,071,645

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial The Regents of the University of Colorado (Denver, CO) 2023-06-12 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 8,071,645

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2004111199 Dec 23, 2004
World Intellectual Property Organization (WIPO) 2004111199 Jan 12, 2006
United States of America 2005020682 Jan 27, 2005
United States of America 2012128724 May 24, 2012
European Patent Office 1651207 May 03, 2006
European Patent Office 1651207 Oct 01, 2008
European Patent Office 2377528 Feb 19, 2014
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cipla
Covington
Boehringer Ingelheim
Johnson and Johnson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.